stockrowEnvista Holdings Corporation
NVST Healthcare Medical Instruments & Supplies
Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024.
- Revenue
- +3.22%
- EPS
- +1,855.6%
- Free cash flow
- −6.48%
- Total debt
- −1.13%
Quarter to September 2026, against a year earlier
Follow NVST
Alert me
Envista Holdings Corporation (NVST) EPS (diluted)
Envista Holdings Corporation's EPS (diluted) for fiscal 2025 was $0.28, compared with −$6.50 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.92. Over the past ten years it has ranged from −$6.50 (fiscal 2024) to $2.35 (fiscal 2017); the current reading is higher than 40% of that period. Envista Holdings Corporation ranks 6th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.28 | — |
| FY2024 | −$6.50 | — |
| FY2023 | −$0.60 | — |
| FY2022 | $1.37 | (28.65%) |
| FY2021 | $1.92 | 860.00% |
| FY2020 | $0.20 | (87.50%) |
| FY2019 | $1.60 | (11.30%) |
| FY2018 | $1.80 | (23.38%) |
| FY2017 | $2.35 | 37.67% |
| FY2016 | $1.71 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $3.16 | 857.58% |
| Jun 2026 | $0.33 | 43.48% |
| Mar 2026 | $0.23 | 15.00% |
| Dec 2025 | $0.20 | — |
| 28 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| NVST Envista Holdings Corporation | $3.92 |
| MMSI Merit Medical Systems, Inc. compare | $2.66 |
| ICUI ICU Medical, Inc. compare | $2.39 |
| STVN Stevanato Group S.p.A. compare | $0.59 |
| ATRC AtriCure, Inc. compare | $0.30 |
| WRBY Warby Parker Inc. compare | $0.06 |
| MMED MiniMed Group, Inc. compare | −$0.59 |
| PLSE Pulse Biosciences, Inc compare | −$1.21 |
| TFX Teleflex Incorporated compare | −$23.29 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NVST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement